
Orphan drug market access in Europe: HTA challenges and the growing potential of RWE
Europe has witnessed strong growth in orphan drug approvals over the past decade, yet for pharmaceutical innovators, securing market access for these rare disease therapies remains challenging without the right support. Dozens of new orphan medicines are …